1
|
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L, Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi M, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontana A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A, Sarobba M, Pugliese P, Bernardo A, Pavese I, Coccaro M, Massidda B, Ionta M, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficorella A, Moscetti L, Vallini I, Giardina G, Silva R, Montedoro M, Seles E, Morano F, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol 2022; 23:1571-1582. [DOI: 10.1016/s1470-2045(22)00632-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 10/06/2022] [Accepted: 10/07/2022] [Indexed: 11/11/2022]
|
2
|
Aitini E. When the Oncologist Becomes the Patient. Curr Oncol 2019; 26:166. [DOI: 10.3747/co.26.4619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
It’s a Saturday afternoon in February. A Saturday afternoon spent waiting for a telephone call from a pathologist, a personal friend.[...]
Collapse
|
3
|
Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, Lusenti A, Bertani M, Morandi C, Benedini V. Intra-Arterial Hepatic Carboplatin-Based Chemotherapy for Ocular Melanoma Metastatic to the Liver. Report of a Phase II Study. Tumori 2018; 80:37-9. [PMID: 8191596 DOI: 10.1177/030089169408000107] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background ocular melanoma tends to metastasize to the liver, sparing for a long time the rest of the organism. Therefore, a regional treatment is especially indicated. Methods eight patients with ocular melanoma metastatic to the liver were treated with intraarterial hepatic carboplatin-based chemotherapy at the dose of 300 mg/m2 once every two weeks at an outpatient clinic. All the patients were submitted to laparotomy with surgical implantation of an arterial port device through the gastroduodenal artery. Results the overall response rate was 38% with a median survival time of 15 months. The regimen was well tolerated and the principle toxicity was myelosuppression; any instance of hepatic and/ or cholangitic damage was reported. Conclusions Carboplatin seems suitable for intraarterial hepatic chemotherapy and active in ocular melanoma metastic to the liver.
Collapse
Affiliation(s)
- M Cantore
- Oncology Department, Civil Hospital of Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Cavazzini G, Colpani F, Cantore M, Aitini E, Rabbi C, Taffurelli M, Pari F, Bellomi A, Bertuzzi A, Smerierl F. Breast Metastasis from Gastric Signet Ring Cell Carcinoma, Mimicking Inflammatory Carcinoma. A Case Report. Tumori 2018; 79:450-3. [PMID: 8171750 DOI: 10.1177/030089169307900617] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We report a case of breast metastasis of signet ring cell gastric cancer clinically presented as a primary inflammatory carcinoma. Metastases to the breast are uncommon; review of the literature demonstrated only 300 cases. The clinical and radiographic features of the metastatic lesion were unlike those reported in the literature. Although a primary signet ring cell breast carcinoma was described, the pathologic patterns of the breast lesion, here reported, lead us to conclude this was a metastasis and not another primary tumor.
Collapse
Affiliation(s)
- G Cavazzini
- Medical Oncology Department, Ospedale Civile Carlo Poma, Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Aitini E, Rabbi C, Mambrini A, Cavazzini G, Pari F, Zamagni D, Cantore M, Pagani M, Sorio M, Lusenti A, Adami F, Smerieri F. Epirubicin, Cisplatin and Continuous Infusion 5-Fluorouracil (ECF) in Locally Advanced or Metastatic Gastric Cancer: A Single Institution Experience. Tumori 2018; 87:20-4. [PMID: 11669552 DOI: 10.1177/030089160108700105] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background The role of chemotherapy in locally advanced or metastatic gastric cancer has been controversial, but chemotherapy has recently been shown to relieve tumor-related symptoms, improve quality of life and prolong survival when compared with best supportive care. Furthermore, palliative chemotherapy is also cost-effective. “Second-generation” combination chemotherapy regimens were developed in the 1980s with high activity in advanced or metastatic gastric cancer (EAP, FAMTX, PELF, ECF). In randomized studies, EAP demonstrated no difference in activity but a significantly higher overall toxicity and toxic death rate than FAMTX, and the ECF (epirubicin, cisplatin, 5-fluorouracil) regimen gave a survival and response advantage, tolerable toxicity, better quality of life and was more cost-effective than FAMTX. Methods Sixty patients with locally advanced or metastatic gastric cancer were treated with the ECF regimen (21 weeks of 5-fluorouracil given by continuous infusion through a central line at 200 mg/m2 for 24-hr combined with cisplatin at 60 mg/m2 iv and epirubicin at 50 mg/m2 iv beginning on day 1 and repeated every 3 weeks for 8 courses). There were 42 males and 18 females, with a median age of 64 years (range, 40-74). The median performance status was 1. The histologic type was adenocarcinoma in 44 patients and undifferentiated carcinoma in 16 (27%). Three patients had locally advanced disease (5%) and 57 had metastatic disease (95%). Seven patients (12%) had received prior chemotherapy for advanced disease. Results All patients were assessable for toxicity and 55 for response (5 had insufficient treatment). Toxicity was mild or moderate, and there was no toxic death. Incidence of WHO toxicity ≥ 2 was nausea and vomiting in 3%, mucositis in 3%, leukopenia in 7%, anemia in 3%, and thrombocytopenia in 2%. Port-a-Cath toxicity was thrombosis in 4, dislocation in 2 and infection in 3 patients. Seven complete responses and 13 partial responses (overall response rate, 36%) were achieved, with a response rate of 39% in untreated and 17% in pretreated patients. Nine patients (16%) had stable disease and 26 (47%) progressive disease. Most patients felt symptomatically improved on ECF. Conclusions Our study confirms that the ECF regimen has a favorable pattern of toxicity and is feasible on an outpatient basis. However, it did not confirm the high response rate reported in other phase II trials.
Collapse
Affiliation(s)
- E Aitini
- Medical Oncology and Hematology Department, Carlo Poma Hospital, Mantua, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fossati R, Alexanian A, Liberati A, Marsoni S, Monferroni N, Nicolucci A, Parazzini F, Giganti M, Piffanelli A, Ghezzi P, Magnanini S, Rinaldini M, Berardi F, Di Biagio G, Testore F, Tavoni N, Palmieri D, Schittulli F, Pedicini T, Fumagalli M, Gritti G, Braga M, Marini G, Zamboni A, Cosentino D, Epifani C, Scognamiglio G, Perroni D, Peradotto F, Saba V, Indelli M, Santini A, Isa L, Scapaticci R, Aitini E, Gavazzini G, Smerieri F, Lomonaco I, Nascimben O, Locatelli E, Monti M, Ghislandi E, Gottardi O, Majno M, Poma C, Pluchinotta A, Armaroli L, Confalonieri C, Viola P, Sisto R, Buda F, Plaino R, Galletto L, Trolli B, Biasio M, Rolfo A, Vaudano G, Giolito M, Scoletta G, Ambrosini G, Busana L, Molteni M, Richetti A. Breast Cancer Estrogen and Progesterone Receptors: Associations with Patients' Clinical and Epidemiologic Characteristics. Tumori 2018; 77:472-8. [DOI: 10.1177/030089169107700605] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A total of 1095 patients with operable breast cancer and en-rolled in a randomized clinical trial were analysed for estrogen (ER) and progesterone (PgR) receptor content of their primary tumor, and the relationships between steroid receptor status and several epidemiologic characteristics were studied. The proportion of ER+ and median ER levels increased with age: compared to women younger than 40, those aged 66 or more were approximately three times more likely to have an ER+ tumor (OR = 3.0, 95% C.I. = 1.6–5.7). This difference tended to be more marked after comparison between patients with ER > 100 fmol/mg protein and ER- within the same age groups: OR = 7.04, 95 % C.I. = 2.89–17.12. No association emerged between age and PgR. ER status and concentrations were independent of menopausal status after adjustment for age, whereas the proportion of PgR+ and PgR levels were significantly lower in postmenopausal patients of the same age. The distribution of ER and PgR profiles was similar in relation to family history of breast cancer, reproductive events and other selected epidemiologic characteristics of the patients.
Collapse
Affiliation(s)
| | - R. Fossati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A.A. Alexanian
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Liberati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - S. Marsoni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - N. Monferroni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Nicolucci
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - F. Parazzini
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - M. Giganti
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | - A. Piffanelli
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Zinzani PL, Mazza P, Gherlinzoni F, Zanchini R, Bocchia M, Aitini E, Cavazzini G, Amurri B, Gobbi M, Tura S. Ceop Regimen in the Treatment of Advanced Low-Grade Non-Hodgkin's Lymphomas: Preliminary Report. Tumori 2018; 76:533-6. [PMID: 2284688 DOI: 10.1177/030089169007600603] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Between March 1987 and December 1988, 30 previously untreated patients with low-grade non-Hodgkin's lymphomas (NHL), according to the Kiel classification, were treated by a combination of therapy including cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP). Eighteen patients (60%) achieved a complete pathologic remission, and 8 patients (26.6%) had a partial response with a reduction of more than 50% of tumor-related manifestations. Four patients (13.4%) were primary resistant to CEOP. The overall survival was 96.6% with a median follow-up of 25 months from the diagnosis; none of the patients who achieved complete response relapsed at a median follow-up of 21 months from the completion of treatment. Clinical and hematologic toxicities were irrelevant. This regimen was effective in inducing a good remission rate of low-grade NHL, but a longer follow-up for definitive conclusions is warranted.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology L. e A. Sergnoli, University of Bologna, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Gastrointestinal autonomic nerve (GAN) tumor is an uncommon specialized form of gastrointestinal stromal tumor (GIST). We report the case of a 46-year-old man affected by this tumor. The neoplasm arose from the sigmoid colon. The patient underwent surgery but eight months later an omental relapse occurred. A second laparotomy was successfully performed and the patient is free of disease at 21 months of follow-up. To our knowledge this is the first case of a large bowel GAN tumor described in the literature.
Collapse
Affiliation(s)
- F Pari
- Department of Oncology and Hematology, Ospedale Carlo Poma, Mantua, Italy.
| | | | | | | | | | | |
Collapse
|
9
|
Aitini E. Communication and Informed Consent ... a Story. Curr Oncol 2017; 24:e339-e340. [DOI: 10.3747/co.24.3531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Someone knocks at the door [...]
Collapse
|
10
|
Pisanelli B, Patruno E, Adovasio A, Adami F, Aitini E. End of life in cancer patients: something more? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv347.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Adovasio A, Aitini E, Ceppi M, Bruzzone M, Pisanelli B, Oliani C, Patruno E, Adami F, Ridolfi R, Gentilini P, Comella G, Castagneto B, Barni S, Labianca R, Crispino S, Porcile G, Gennaro V. Cancer Registries Underestimate both the Type of Disease and also Number of Cases due to Pollution. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Pegoraro M, Barana D, Schiavo G, Fracca I, Giabardo C, Forni C, Padovani M, Binato S, Magazù M, Aitini E, Adami F, Ridolfi R, Porcile G, Oliani C. Style modification in breast and Colorectal Cancer Patients: results of a pilot study Long-Survivors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Adami F, Porcile G, Ridolfi R, Labianca R, Palazzo S, Bretti S, Gentilini P, Carbonardi F, Oliani C, Aitini E. Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Porcile G, Aitini E, Bretti S, Crispino S, Oliani C, Romizi R, Cova D, Savia F, Clerico M, Palazzo S, Labianca R, Adami F. “Green oncology”: a new paradigm for medical oncology. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Aitini E. The Chronic Condition of Life. Curr Oncol 2015; 22:e323-4. [DOI: 10.3747/co.22.2282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The young branches of the poplar trees moved lazily, wrapped in the pale blue spring, embraced by a soft breeze. [...]
Collapse
|
16
|
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014; 25:1373-1378. [PMID: 24728035 DOI: 10.1093/annonc/mdu146] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [irinotecan plus 5-fluorouracil/folinic acid (5-FU/LV)] followed by docetaxel plus cisplatin improves disease-free survival in comparison with 5-FU/LV in patients with radically resected gastric cancer. PATIENTS AND METHODS Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to either FOLFIRI (irinotecan 180 mg/m(2) day 1, LV 100 mg/m(2) as 2 h infusion and 5-FU 400 mg/m(2) as bolus, days 1 and 2 followed by 600 mg/m(2)/day as 22 h continuous infusion, q14 for four cycles) followed by docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, q21 for three cycles (sequential arm) or De Gramont regimen (5-FU/LV arm). RESULTS From February 2005 to August 2009, 1106 patients were enrolled, and 1100 included in the analysis: 562 in the sequential arm and 538 in the 5-FU/LV arm. With a median follow-up of 57.4 months, 581 patients recurred or died (297 sequential arm and 284 5-FU/LV arm), and 483 died (243 and 240, respectively). No statistically significant difference was detected for both disease-free [hazard ratio (HR) 1.00; 95% confidence interval (CI): 0.85-1.17; P = 0.974] and overall survival (OS) (HR 0.98; 95% CI: 0.82-1.18; P = 0.865). Five-year disease-free and OS rates were 44.6% and 44.6%, 51.0% and 50.6% in the sequential and 5-FU/LV arm, respectively. CONCLUSIONS A more intensive regimen failed to show any benefit in disease-free and OS versus monotherapy. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01640782.
Collapse
Affiliation(s)
- E Bajetta
- Istituto di Oncologia, Policlinico di Monza, Monza
| | - I Floriani
- Laboratory of Clinical Research, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano.
| | - M Di Bartolomeo
- Struttura Complessa di Medicina Oncologica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
| | - R Labianca
- Unità di Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo
| | - A Falcone
- Dipartimento di Ricerca Traslazionale, Università di Pisa, Istituto Toscano Tumori, Pisa
| | - F Di Costanzo
- S.C. Oncologia Medica, Azienda Ospedaliero-Universitaria Careggi, Firenze
| | - G Comella
- Oncologia Medica A, Fondazione Pascale, Istituto Nazionale dei Tumori, Napoli
| | - D Amadori
- I.R.C.C.S. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola
| | - C Pinto
- U.O. di Oncologia Medica, Policlinico S.Orsola Malpighi, Bologna
| | - C Carlomagno
- Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Napoli
| | - D Nitti
- Clinica Chiurgica 1, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Padova
| | - B Daniele
- Dipartimento di Oncologia, A.O.G. Rummo, Benevento
| | - E Mini
- Dipartimento di Scienze Della Salute, Sezione di Farmacologia Clinica e Oncologia, Università degli Studi di Firenze, Firenze
| | - D Poli
- Laboratory of Clinical Research, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano
| | - A Santoro
- U.O. Oncologia e Ematologia, Humanitas Cancer Center, Istituto Clinico Humanitas-I.R.C.C.S., Rozzano
| | - S Mosconi
- Unità di Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo
| | - R Casaretti
- S.C. di Oncologia Medica Addominale, dell'Istituto Tumori di Napoli, Napoli
| | - C Boni
- Oncologia, Arcispedale Santa Maria Nuova-I.R.C.C.S., Reggio Emilia, Reggio Emilia
| | - G Pinotti
- Divisione di Oncologia Medica, A.O. Ospedale di Circolo, Varese
| | - P Bidoli
- S.C. Oncologia Medica, A.O.S. Gerardo, Monza
| | - L Landi
- U.O. Oncologia Medica, Azienda USL6 di Livorno, Istituto Toscano Tumori, Livorno
| | - G Rosati
- Unità Oncologia Medica, Ospedale S. Carlo, Potenza
| | - A Ravaioli
- U.O. di Oncologia, Ospedale Infermi Rimini, Ospedale Cervesi, Azienda USL di Rimini, Rimini, Cattolica
| | - M Cantore
- Oncologia Medica, USL 1, Massa Carrara
| | - F Di Fabio
- U.O. di Oncologia Medica, Policlinico S.Orsola Malpighi, Bologna
| | - E Aitini
- Ospedale Carlo Poma, Mantova, Italy
| | - A Marchet
- Clinica Chiurgica 1, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Padova
| |
Collapse
|
17
|
Milella M, Di Lorenzo G, Felici A, Aieta M, Re GL, Boni C, Aitini E, Villa E, De Placido S, Cognetti F. Medical Optimization of Torisel® (MOTOR): A Phase II Trial of Temsirolimus as Second-Line Treatment for Advanced RCC by the Italian Kidney Cancer Group (GIR). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33418-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
18
|
Buzzoni R, Pusceddu S, Biondani P, Cantore M, Aitini E, Bertolini A, Alabiso O, Isa L, Pinotti G, Bajetta E. 6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71937-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Venturini M, Del Mastro L, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Boni C, Levaggi A, Scalamogna R, Galli A, Clavarezza M. Abstract P1-11-20: Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC→Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-11-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There is strong evidence that VEGF plays an important role in the pathogenesis and progression of human breast cancer. Bevacizumab, a monoclonal antibody, specifically inhibits VEGF. The combination of first-line bevacizumab with chemotherapy significantly improved the activity in comparison to chemotherapy alone in three randomized phase III trials in metastatic breast cancer patients (pts). In early breast cancer, the FEC→Paclitaxel regimen is a highly active standard therapy. Therefore we initiated a trial to evaluate the combination of bevacizumab with this efficacious chemotherapy regimen for the treatment of stage III or inflammatory early breast cancer (LABC).
Patients and Methods: The study is designed to evaluate a sequential regimen of FEC90 followed by the combination of paclitaxel and bevacizumab as neoadjuvant therapy in patients with HER2-negative locally advanced (stage III or inflammatory) breast cancer. Patients are treated with neoadjuvant FEC 600/90/600 mg/m2 q21d x 4, followed by paclitaxel 80 mg/m2 weekly x 12 combined with bevacizumab 10 mg/kg q2w x 6. Patients undergo surgery 4 weeks after completing chemotherapy. Pathologic complete response (pCR), the primary endpoint, is defined as no evidence of invasive tumor in the final surgical sample both in the breast and axilla. Secondary endpoints include objective clinical response rate (RR), disease-free interval, overall survival, rate of breast-conserving surgery, and the safety of the regimen.
Results: Between Feb 2008 and Dec 2009, 54 pts (mean age of 51±7.5 years) were enrolled into the study. To date, 32 pts have completed neoadjuvant treatment and surgery and are evaluable for response. Baseline characteristics in these 32 patients were as follows: cT3/cT4b: 20 (63%) and/or cN2/cN3: 14 (43%); estrogen receptor (ER) positive: 24 (75%) and 8 (25%) triple-negative (TN), defined as ER negative, progesterone receptor-(PgR-) negative, and HER2 negative. Histological type was ductal carcinoma in 24 patients (75%), lobular carcinoma in 4 (13%), inflammatory breast cancer in 1 (3%), and other in 3 (9%). Mastectomy was performed in 22 patients (69%) and breast-conserving surgery in 10 patients (31%). After neoadjuvant treatment, 8/32 patients (25%) achieved a pCR.
Conclusions: This open-label, multicenter, phase II study demonstrated that the FEC→Paclitaxel plus bevacizumab combination is a highly active neoadjuvant treatment for HER2-negative locally advanced breast cancer. A 25% of pCR in this group of pts with high tumor burden, i.e. the LABC, is oneof the most promising chemotherapeutic regimen if confirmed in the final analyis. Results for all 54 pts enrolled will be presented at the meeting.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-20.
Collapse
Affiliation(s)
- M Venturini
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - L Del Mastro
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - E Aitini
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - S Saracchini
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - O Garrone
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - A Durando
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - S De Placido
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - C Boni
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - A Levaggi
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - R Scalamogna
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - A Galli
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| | - M. Clavarezza
- Ospedale Sacro Cuore-Don Calabria, Negrar, VR, Italy; Istituto Nazionale Ricerca Cancro, Genova, Italy; Ospedale C. Poma, Mantova, Italy; Ospedale S. Maria degli Angeli, Pordenone, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale S.Anna, Torino, Italy; Università Federico II, Napoli, Italy; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Medical Affairs, Monza, Italy
| |
Collapse
|
20
|
Guarneri V, Frassoldati A, Gebbia V, Bisagni G, Cavanna L, Donadio M, Lelli G, Musolino A, Colucci G, Banna GL, Degli Esposti R, Ferro A, Grasso F, Zamagni C, Amadori D, Aieta M, Molino A, Garrone O, Aitini E, Fornari G, Cascinu S, Rossi G, D'Amico R, Conte PF. Abstract P5-12-05: 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Several large randomized trials have shown the superiority of combining trastuzumab with chemotherapy versus chemotherapy alone as adjuvant treatment for HER2+ breast cancer patients. We are running a large phase III trial comparing two different trastuzumab durations (Short-HER study). We are reporting the preliminary cardiac safety data.
Methods: The Short-HER study is a phase III, multicentric, Italian trial where 2500 HER2+ breast cancer patients will be randomized to: Arm A (Long) 4 courses of anthracycline based chemotherapy (AC or EC) followed by 4 courses of docetaxel in combination with trastuzumab, followed by 14 additional courses of 3-weekly trastuzumab; or Arm B (Short) 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab followed by FEC x3. this is a non-inferiority trial with DFS and OS as primary end points, and 2-yr failure rate and incidence of cardiac events as secondary end points. Left ventricular ejection fraction (LVEF) is measured at baseline, at the end of each sequence of chemotherapy in both arms, and after 9 and 12 months since randomization thereafter. A cardiac event (CE) was defined as the occurrence of any of the followings: 1) LVEF decrease of more than 15 percentage points from baseline ; 2) LVEF decrease of more than 10 percentage points with absolute value below 50%; 3) symptomatic cardiac failure; 4) other cardiac side effects of grade 2 or more.
Results: 510 patients from 69 Italian centers have been randomized so far, 251 in arm A (long) and 259 in Arm B (Short). 146 patients enrolled in arm A and 150 patients enrolled in arm B have received at least 3 months of therapy, and are eligible for the present analysis. In arm A (long), 20 patients (13.7%) experienced a CE: 12 patients experienced a LVEF decline of > 15 percentage points (5 patients with LVEF below 50%, one patient with concomitant atrial fibrillation); 3 patients had a LVEF decline of >10 percentage points with an absolute value below 50%. One patient had symptomatic cardiac failure. Two patients developed Grade 2 hypertension. Two patients developed Grade 2 arrhythmia.
In arm B (short), 11 patients (7.3%) experienced a CE: 7 patients had a LVEF decline of > 15 percentage points; one patient had a LVEF decline of > 10 percentage points with an absolute value below 50%. Three patients developed Grade 2 arrhythmia
Conclusions: This is a non-inferiority study designed on the assumption that a shorter treatment duration is associated with a significantly lower incidence of cardiac events. With 9 clinically relevant CEs (symptomatic cardiac failure or LVEF below 50%) in arm A (Long) and 1 in arm B (Short), these preliminary data support the assumption, and recruitment is ongoing.
Supported by Agenzia Italiana del FArmaco (AIFA).
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-12-05.
Collapse
Affiliation(s)
- V Guarneri
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - A Frassoldati
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - V Gebbia
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - G Bisagni
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - L Cavanna
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - M Donadio
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - G Lelli
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - A Musolino
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - G Colucci
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - GL Banna
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - R Degli Esposti
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - A Ferro
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - F Grasso
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - C Zamagni
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - D Amadori
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - M Aieta
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - A Molino
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - O Garrone
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - E Aitini
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - G Fornari
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - S Cascinu
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - G Rossi
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - R D'Amico
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| | - PF. Conte
- Modena University Hospital, Italy; La Maddalena Hospital, Palermo; S Maria Nuova Hospital, Reggio Emilia; Hospital of Piacenza; San Giovanni Battista Hospital, Torino; S. Anna Hospital, Ferrara; Medical Oncology Unit, University Hospital of Parma; Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy; Vittorio Emanuele University Hospital, Catania; Bellaria Hospital, University of Bologna; Hospital of Trento; Hospital of Aosta; Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna; Istituto Scientifico Romagnolo perlo Studio e la Cura dei Tumori, Meldola; Hospital of Rionero in Vulture; OCM, Verona University Hospital; Oncology Division, Santa Croce-Carle Hospital, Cuneo; Hospital of Mantova; Ospedale Evangelico Valdese, Torino; Ancona University Hospital; Hospital of Guastalla
| |
Collapse
|
21
|
Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro L. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast 2010; 19:333-8. [PMID: 20185313 DOI: 10.1016/j.breast.2010.01.018] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Revised: 12/23/2009] [Accepted: 01/22/2010] [Indexed: 01/07/2023] Open
Abstract
To evaluate the cardiotoxicity, general toxicity, and activity of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first-line therapy in metastatic breast cancer. Thirty-one patients with metastatic human epidermal growth factor receptor 2-overexpressing breast cancer, who had not previously received chemotherapy for metastatic disease, received non-pegylated liposomal doxorubicin (50 mg/m(2)), docetaxel (75 mg/m(2)) and trastuzumab (2 mg/kg/week) for up to eight cycles, followed by trastuzumab alone for up to 52 weeks. Cardiotoxicity was defined as a decrease in left ventricular ejection fraction (LVEF) to below 45%, or a decrease in LVEF of at least 20% from baseline. Mean LVEF was maintained at baseline level also in the subset of patients who had received anthracycline previously. Cardiotoxicity developed in three patients during the treatment cycles, and in two further patients after the end of the study. The most common adverse events were haematological toxicity, alopecia, asthenia and fever. The best overall response rate was 65.5%. Median time to progression was 13.0 months. The combination of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab combines acceptable cardiac and general toxicity and promising activity as first-line therapy in metastatic breast cancer.
Collapse
Affiliation(s)
- M Venturini
- Oncologia Medica, Ospedale Classificato Sacro Cuore Don Calabria, Via Don A. Sempreboni 5, Negrar, Verona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2009; 102:68-72. [PMID: 19935794 PMCID: PMC2813746 DOI: 10.1038/sj.bjc.6605458] [Citation(s) in RCA: 169] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma. METHODS We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma. Sorafenib was administered at a dose of 400 mg twice a day. The primary end point was the disease control rate at 12 weeks. RESULTS A total of 46 patients were treated. In all, 26 (56%) had received chemotherapy earlier, and 36 patients completed at least 45 days of treatment. In intention-to-treat analysis, the objective response was 2% and the disease control rate at 12 weeks was 32.6%. Progression-free survival (PFS) was 2.3 months (range: 0-12 months), and the median overall survival was 4.4 months (range: 0-22 months). Performance status was significantly related to PFS: median PFS values for ECOG 0 and 1 were 5.7 and 2.1 months, respectively (P=0.0002). The most common toxicities were skin rash (35%) and fatigue (33%), requiring a dose reduction in 22% of patients. CONCLUSIONS Sorafenib as a single agent has a low activity in cholangiocarcinoma. Patients having a good performance status have a better PFS. The toxicity profile is manageable.
Collapse
Affiliation(s)
- C Bengala
- Division of Medical Oncology, University Hospital, University of Modena and Reggio Emilia, 41100 Modena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009; 20:1249-56. [PMID: 19276396 DOI: 10.1093/annonc/mdn774] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in advanced non-small-cell lung cancer, in terms of time to treatment failure (TTF), overall response, progression-free survival (PFS), overall survival (OS), tolerance and quality of life (QoL). METHODS Patients were randomly assigned to receive cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks, after a first cycle of NVBiv 25 mg/m2 on day 1 and NVBo 60 mg/m2 on day 8 (arm A) or cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B), for a maximum of six cycles in both arms. RESULTS From 2 February 2004 to 1 January 2006, 390 patients were entered in a randomised study and 381 were treated. The patient characteristics are as follows (arms A/B): metastatic (%) 80.5/84.8; patients with three or more organs involved (%) 45.3/40.8; median age 59.4/62.1 years; male 139/146; squamous (%) 34.2/33.5; adenocarcinoma (%) 41.6/39.3; median TTF (arms A/B in months) [95% confidence interval (CI)]: 3.2 (3.0-4.2), 4.1 (3.4-4.5) (P = 0.19); overall response (arms A/B) (95% CI): 27.4% (21.2% to 34.2%), 27.2% (21.0% to 34.2%); median PFS (arms A/B in months) (95% CI): 4.9 (4.4-5.9), 5.1 (4.3-6.1) (P = 0.99) and median OS (arms A/B in months) (95% CI): 9.9 (8.4-11.6), 9.8 (8.8-11.5) (P = 0.58). The median survival for squamous histology was 8.87/9.82 months and for adenocarcinoma 11.73/11.60 months for arms A and B, respectively. Main haematological toxicity was grade 3-4 neutropenia: 24.4% (arm A) and 28.8% (arm B). QoL as measured by the Lung Cancer Symptom Scale was similar in both arms. CONCLUSIONS Both arms provided similar efficacy in terms of response, time-related parameters and QoL, with an acceptable tolerance profile. In the current Global Lung Oncology Branch trial 3, NVBo was shown to be effective as a substitute for the i.v. formulation. This can relieve the burden of the i.v. injection on day 8 and can optimise the hospital's resources and improve patient convenience.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Vanturini M, Bighin C, Puglisi F, Contu A, Aitini E, Colucci G, Merlano MC, Paccagnella A, Marini G, Crinò L, Djazouli K, Barbato A. A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3156
The objective of the phase II study is to evaluate the cardiotoxicity, general safety, and efficacy of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first line treatment of metastatic breast cancer.
 Patients and methods: Patients (n = 31) with metastatic HER2-overexpressing breast cancer, who had not previously received chemotherapy for metastatic disease, received non-pegylated liposomal doxorubicin (50 mg/m2), docetaxel (75 mg/m2) every 3 weeks and trastuzumab (2 mg/kg/week) for up to eight cycles, followed by trastuzumab alone for up to 52 weeks. Cardiotoxicity was defined as signs and/or symptoms of congestive heart failure (CHF) and/or an absolute decrease in left ventricular ejection fraction (LVEF) of ≥ 20 units or a decline to ≤ 45%. Patients were allowed to receive adjuvant doxorubicin or epirubicin to cumulative doses up to 240 mg/m2 or 450 mg/m2, respectively.
 Results: The mean LVEF at baseline was 62.8 ± 7.1% and decreased to 60.2 ± 6.5% at cycle 2, but did not change significantly during the rest of the study; mean values at cycle 8 and at the end of the study were 58.7 ± 7.0% and 57.3 ± 9.5% respectively. One case of symptomatic CHF occurred during the study.
 The most common adverse events were hematologic toxicities, alopecia, asthenia and fever. The Overall Response Rate was 65.5% (CR 31%, PR 34.5%).The median progression free survival was 15.5 months (95% CI 11-24 months). The average overall survival was 27.9 months.Conclusions: These results suggest that the combination of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab has shown a good cardiac safety profile at a long term follow up, comparatively to recent published results data in HET study. A promising efficacy including CR and PFS has been noted in 1st line MBC.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3156.
Collapse
Affiliation(s)
- M Vanturini
- 1 Oncology, Ospedale Classificato Sacro Cuore Don Calabria, Negrar-Verona, Italy
| | - C Bighin
- 2 Isitituto Tumori di Genova, Genova, Italy
| | - F Puglisi
- 3 Policlinico Universitario, Udine, Italy
| | - A Contu
- 4 Ospedale Civico, Sassari, Italy
| | - E Aitini
- 5 Ospedale Carlo Poma, Mantova, Italy
| | | | - MC Merlano
- 7 Ospedale Santa Croce e Carle, Cuneo, Italy
| | | | - G Marini
- 9 Spedali Civili, Brescia, Italy
| | - L Crinò
- 10 Azienda Ospedaliera, Perugia, Italy
| | | | | |
Collapse
|
25
|
Gebbia V, Morena R, Frontini L, Aitini E, Daniele B, Gamucci T, Di Maio M, Morabito A, Gallo C, Gridelli C. The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X) as second-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Cortesi E, Barni S, Massidda B, Aitini E, Colucci G, Gridelli C, Iacono C, Lorusso V, Maltoni M, Pronzato P. How Italian oncologists cope with end-of-life care: A pilot study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Del Mastro L, Costantini M, Durando A, Michelotti A, Danese S, Aitini E, Olmeo N, Pronzato P, Venturini M. Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.516] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Dealis C, Bertolini F, Malavasi N, Zironi S, Boni C, Banzi M, Aitini E, Cavazzini G, Luppi G, Conte PF. A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4590] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Del Mastro L, Dozin B, Aitini E, Catzeddu T, Baldini E, Contu A, Durando A, Danese S, Cavazzini G, Canavese G, Bruzzi P, Pronzato P, Venturini M. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group. Ann Oncol 2008; 19:299-307. [DOI: 10.1093/annonc/mdm475] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2007; 19:370-3. [PMID: 18156144 DOI: 10.1093/annonc/mdm501] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM). PATIENTS AND METHODS Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero. RESULTS Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3-34.7]. In all, 29 (39%) (95% CI 28-48) patients reported stable disease. The median survival was estimated at 14 months. CONCLUSION This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.
Collapse
Affiliation(s)
- B Castagneto
- Department of Oncology, Novi Ligure Hospital, viale Giolitti, Novi Ligure (AL), Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Galli L, Fontana A, Galli C, Landi L, Fontana E, Antonuzzo A, Andreuccetti M, Aitini E, Barbieri R, Di Marsico R, Falcone A. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer 2007; 97:1613-7. [PMID: 18026196 PMCID: PMC2360275 DOI: 10.1038/sj.bjc.6604090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30 mg m−2 intravenous (i.v.), weekly, plus estramustine 280 mg twice daily for 12 weeks. After 2 weeks rest, patients with a decline or stable PSA were treated with mitoxantrone 12 mg m−2 i.v. every 3 weeks plus prednisone 5 mg twice daily for 12 cycles. Forty patients were assessable for toxicity after docetaxel/estramustine. Main toxicities were grade 3–4 AST/ALT or bilirubin increase in seven patients (17.5%) and deep venous thrombosis (DVT) in four patients (10%). Twenty-seven patients received mitoxantrone/prednisone. Main toxicities included DVT in one patient (3.7%) and congestive heart failure in two patients (7%). Thirty-nine patients were assessable for PSA response. Twenty-nine patients (72.5%; 95% CI 63–82%) obtained a ⩾50% PSA decline with 15 patients (37.5%; 95% CI 20–50%) that demonstrated a ⩾90% decrease. Median progression-free and overall survival were respectively 7.0 (95% CI 5.8–8.2 months) and 19.2 months (95% CI 13.9–24.3 months). In conclusion, although this regimen demonstrated a favourable toxicity profile, sequential administration of mitoxantrone is not able to improve docetaxel activity in patients with HRPC.
Collapse
Affiliation(s)
- L Galli
- Division of Medical Oncology, Azienda USL 6 of Livorno, Livorno 57100, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cascinu S, Berardi R, Siena S, Labianca R, Falcone A, Aitini E, Barni S, Di Costanzo F, Frontini L, Tonini G, Zaniboni A. The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4544] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4544 Background: Cetuximab, an EGFR antibody inhibitor, has been shown to increase the activity of gemcitabine (GEM) in APC. Based on data from randomised trials and meta-analyses suggesting that the combination of a GEM with a platinum analog significantly improves survival as compared to GEM alone, we assessed the activity and feasibility of a combination of GEM/cisplatin (CDDP) plus cetuximab. Methods: Multicenter, randomised two-arm phase II trial: GEM 1,000 mg/m2 day 1,8 and CDDP 35 mg/m2 day 1,8 every 21 days alone or in combination with cetuximab 250 mg/m2 weekly after a loading dose of 400 mg/m2. Treatment was limited to a maximum of 9 cycles. With 37 patients in each arm the power was 90% to select the truly better arm if the true between arm difference in response rate (RECIST) is at least 15%. The study was open for accrual until June 2005. Results: We present here the results of 74 patients including in the study. In all the patients, the first response rate are available (investigators’ assessment after 3 cycles) as well as toxicity data. Conclusions: Cetuximab does not seem to positively interact with GEM/CDDP combination in terms of activity especially concerning time to progression. Although toxicity was not increased by cetuximab, this combination should not be assessed in a phase III trial.The trial was supported in part by by Merck KGaA. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Cascinu
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - R. Berardi
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - S. Siena
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - R. Labianca
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - A. Falcone
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - E. Aitini
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - S. Barni
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - F. Di Costanzo
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - L. Frontini
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - G. Tonini
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| | - A. Zaniboni
- Universita Politecnica delle Marche, Ancona, Italy; Azienda Ospedaliera Cà Granda, Milan, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Azienda USL 6, Livorno, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; Azienda Ospedaliera Treviglio, Treviglio, Italy; Azienda Ospedaliera Careggi, Firenze, Italy; Ospedale S.Gerardo, Monza (MI), Italy; Li. Ist. Univ. Campus Biomedico, Roma, Italy; Casa di Cura Poliambulanza, Brescia, Italy
| |
Collapse
|
33
|
Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullurà D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007; 18:461-7. [PMID: 17110590 DOI: 10.1093/annonc/mdl415] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity. PATIENTS AND METHODS We evaluated the response rate safety of new platinum analogue regimens, randomizing 147 patients with nonoperable IIIB/IV NSCLC to (i) carboplatin (area under the curve = 5 mg min/ml) on day 1 plus gemcitabine (GEM) (1000 mg/m(2)) on days 1 and 8 for six cycles; (ii) same regimen for three cycles followed by docetaxel (Taxotere) (40 mg/m(2)) on days 1 and 8 plus GEM (1250 mg/m(2)) on days 1 and 8 for three cycles; (iii) oxaliplatin (130 mg/m(2)) on day 1 plus GEM (1250 mg/m(2)) on days 1 and 8 for six cycles. RESULTS Intention-to-treat objective response rates were 25%, 25% and 30.6% in arms A, B and C, respectively. Median survival was 11.9, 9.2 and 11.3 months in arms A, B and C, respectively. Grade 3/4 neutropenia/anemia occurred in 29%/12.5%, 10%/16.5% and 8%/6% of arms A, B and C, respectively; grade 3/4 thrombocytopenia in 20.5%, 16.5% and 6%; grade 1/2 neurological toxicity in 43% of arm C. CONCLUSIONS Oxaliplatin/GEM (arm C) had similar activity to carboplatin/GEM (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplatin/GEM in patients not suitable for cisplatin. The sequential regimen gave no additional benefit.
Collapse
Affiliation(s)
- P Bidoli
- Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori i, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007; 96:439-44. [PMID: 17245343 PMCID: PMC2360030 DOI: 10.1038/sj.bjc.6603493] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX). One hundred and forty-three patients with measurable, non-resectable metastatic colorectal cancer were randomised in a multicentre study to receive TEGAFIRI (UFT 250 mg m−2 day days 1–14, LV 90 mg day days 1–14, irinotecan 240 mg m−2 day 1; q21) or TEGAFOX (UFT 250 mg m−2 day days 1–14, LV 90 mg day days 1–14, oxaliplatin 120 mg m−2 day 1; q21). Among 143 randomised patients, 141 were analysed (68 received TEGAFIRI and 73 TEGAFOX). The main characteristics of the two arms were well balanced. The most common grade 3–4 treatment-related adverse events were neutropenia (13% of cases with TEGAFIRI; 1% in the TEGAFOX group). Diarrhoea was prevalent in the TEGAFIRI arm (16%) vs TEGAFOX (4%). Six complete remission (CR) and 19 partial remission (PR) were recorded in the TEGAFIRI arm (odds ratio (OR): 41.7; 95% confidence limit (CL), 29.1–55.1%), and six CR and 22 PR were recorded in the TEGAFOX group, (OR: 38.9; 95% CL, 27.6–51.1). At a median time follow-up of 17 months (intequartile (IQ) range 12–23), a median survival probability of 20 and 19 months was obtained in the TEGAFIRI and TEGAFOX groups, respectively. Median time to progression was 8 months for both groups. TEGAFIRI and TEGAFOX are both effective and tolerable first-line therapies in MCRC patients. The employment of UFT/LV given in doublet combination is interesting and the presented data appear comparable to equivalent infusion regimens described in the literature. The safety profile of the two combinations also allows an evaluation with other biological agents such as monoclonal antibodies.
Collapse
Affiliation(s)
- E Bajetta
- Department of Medical Oncology, Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milano, Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
|
37
|
Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 2005; 93:7-14. [PMID: 15970926 PMCID: PMC2361477 DOI: 10.1038/sj.bjc.6602660] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
No data are available on the role of HER2 overexpression in predicting the efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. We retrospectively evaluated this role in patients enrolled in a phase III study comparing standard FEC21 (5-fluorouracil, epirubicin, and cyclophosphamide, administered every 3 weeks) vs dose-dense FEC14 (the same regimen repeated every 2 weeks). HER2 status was determined for 731 of 1214 patients. Statistical analyses were performed to test for interaction between treatment and HER2 status with respect to event-free survival (EFS) and overall survival (OS); EFS and OS were compared within each HER2 subgroup and within each treatment arm. Median follow-up was 6.7 years. Among FEC21-treated patients, both EFS (HR=2.07; 95% CI 1.27-3.38) and OS (HR=2.47; 95% CI 1.34-4.57) were significantly worse in HER2 + patients than in HER2 - patients. Among FEC14-treated patients, differences in either EFS (HR=1.21; 95% CI 0.65-2.24) or OS (HR=1.85; 95% CI 0.88-3.89) between HER2 + and HER2 - patients were not statistically significant. Interaction analysis suggested that the use of dose-dense FEC14 might remove the negative prognostic effect of HER2 overexpression on EFS and OS. Our data suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the need to confirm this hypothesis in future prospective studies.
Collapse
Affiliation(s)
- L Del Mastro
- Department of Medical Oncology, National Cancer Research Institute, Genoa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [PMID: 15908661 DOI: 10.1200/jco.2005.06.023] [Citation(s) in RCA: 704] [Impact Index Per Article: 37.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer. PATIENTS AND METHODS Patients with advanced pancreatic cancer were stratified according to center, performance status, and type of disease (locally advanced v metastatic) and randomly assigned to either GemOx (gemcitabine 1 g/m2 as a 100-minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2-hour infusion on day 2 every 2 weeks) or Gem (gemcitabine 1 g/m2 as a weekly 30-minute infusion). RESULTS Three hundred twenty-six patients were enrolled; 313 were eligible, and 157 and 156 were allocated to the GemOx and Gem arms, respectively. GemOx was superior to Gem in terms of response rate (26.8% v 17.3%, respectively; P = .04), progression-free survival (5.8 v 3.7 months, respectively; P = .04), and clinical benefit (38.2% v 26.9%, respectively; P = .03). Median overall survival (OS) for GemOx and Gem was 9.0 and 7.1 months, respectively (P = .13). GemOx was well tolerated overall, although a higher incidence of National Cancer Institute Common Toxicity Criteria grade 3 and 4 toxicity per patient was observed for platelets (14.0% for GemOx v 3.2% for Gem), vomiting (8.9% for GemOx v 3.2% for Gem), and neurosensory symptoms (19.1% for GemOx v 0% for Gem). CONCLUSION These results confirm the efficacy and safety of GemOx, but this study failed to demonstrate a statistically significant advantage in terms of OS compared with Gem. Because GemOx is the first combined treatment to be superior to Gem alone in terms of clinical benefit, this promising regimen deserves further development.
Collapse
Affiliation(s)
- C Louvet
- Service d'Oncologie, Hôpital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Cascinu S, Labianca R, Barone C, Santoro A, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Floriani I. High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Cascinu
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - R. Labianca
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - C. Barone
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - A. Santoro
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - V. Catalano
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - O. Bertetto
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - S. Barni
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - L. Frontini
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - E. Aitini
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - I. Floriani
- Univ Politecnica delle Marche, Ancona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; Università Cattolica Gemelli, ROMA, Italy; Inst di ricerca Scientifica Humanitas, Rozzano (Milano), Italy; Osp Lombroso, Pesaro, Italy; Osp Le Molinette, Torino, Italy; Osp Treviglio-Caravaggio, Treviglio (BG), Italy; Osp S. Gerardo, Monza (MI), Italy; Osp C. Poma, Mantova, Italy; Inst di Ricerche Farmacologiche Mario Negri, Milano, Italy
| |
Collapse
|
40
|
Bidoli P, Cortinovis D, Isa L, Fusi A, Pari F, Cullurà D, Aitini E, Pessa S, Formisano B, Bajetta E. Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Bidoli
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cortinovis
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - L. Isa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - A. Fusi
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - F. Pari
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cullurà
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Aitini
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - S. Pessa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - B. Formisano
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Bajetta
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| |
Collapse
|
41
|
Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Aitini E, Marangolo M. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. J Exp Clin Cancer Res 2003; 22:51-7. [PMID: 16767907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Gemcitabine is considered the golden standard treatment for unresectable pancreatic adenocarcinoma. Intra-arte-rial drug administration had shown a deep rationale with some interesting results. In a multicenter phase III trial, we compared gemcitabine given weekly with a combination of 5-fluoruracil, leucovorin, epirubicin, carboplatin (FLEC) administered intra-arteriously as first-line therapy in unresectable pancreatic adenocarcinoma. Patients were randomly assigned to receive gemcitabine at a dose of 1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks or 5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arteriously at three-weekly interval for 3 times. The primary end point was overall survival, while time to treatment failure, response rate, clinical benefit response were secondary endpoints. Sixty-seven patients were randomly allocated gemcitabine and 71 were allocated FLEC intra-arterially. Patients treated with FLEC lived for significantly longer than patients on gemcitabine (p=.036). Survival at 1 year was increased from 21% in the gemcitabine group to 35% in the FLEC group. Median survival was 7.9 months in the FLEC group and 5.8 months in the gemcitabine group. Median time to treatment failure was longer with FLEC (5.3 vs 4.2 months for FLEC vs gemcitabine respectively; p=.013). Clinical benefit was similar in both groups (17.9% for gemcitabine and 26.7% for FLEC; p=NS). CT-scan partial response was similar in both group (5.9% for gemcitabine and 14% for FLEC; p=NS). Toxicity profiles were different. Compared with gemcitabine, FLEC regimen given intra-arteriously, improved survival in patient with unresectable pancreatic adenocarcinoma.
Collapse
Affiliation(s)
- M Cantore
- Oncological Department, USL 1, Massa e Carrara, Empoli.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Cantore M, Rabbi C, Guadagni S, Zamagni D, Aitini E. Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma. Ann Oncol 2002; 13:1687-8. [PMID: 12377661 DOI: 10.1093/annonc/mdf262] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
43
|
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13:1364-9. [PMID: 12196361 DOI: 10.1093/annonc/mdf208] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Among the third-generation chemotherapy regimens specifically adapted in the last decade for elderly aggressive non-Hodgkin's lymphoma (NHL) patients, we designed an 8-week cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin and prednisone (VNCOP-B) plus granulocyte colony-stimulating factor (G-CSF) regimen which, in a national multicenter trial, induced good complete response (CR) and relapse-free survival rates with only moderate toxic effects. Here we report a prospective, multicenter, randomized trial comparing the efficacy and toxicity of 8- and 12-week regimens of VNCOP-B plus G-CSF. PATIENTS AND METHODS From February 1996 to June 2001, 306 consecutive previously untreated stage II-IV aggressive NHL patients > or =60 years of age were enrolled from 12 Italian cooperative institutions. Of the 297 evaluable patients, 149 and 148 received 8- and 12-week regimens, respectively, of VNCOP-B. RESULTS The CR rates were 63% and 56% in the 8- and 12-week groups; at a median of 32 months (range 3-62 months), relapse-free survival rates were 59% and 55%, respectively. Hematological and non-hematological toxicities were similar in both treatment groups. CONCLUSIONS Our data show that extending induction treatment with the VNCOP-B plus G-CSF regimen from 8 to 12 weeks does not raise the CR rate or provide a more durable remission.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology 'Seràgnoli', University of Bologna, Bologna.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13:299-307. [PMID: 11886009 DOI: 10.1093/annonc/mdf040] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The aim of this study was to determine the efficacy of the EAP regimen (etoposide, adriamycin and cisplatin) followed by the Machover schedule (fluorouracil and folinic acid) given as adjuvant treatment to patients with poor prognostic factors (N+ or T3/4). PATIENTS AND METHODS Before randomisation, the subjects were stratified on the basis of node involvement (N+ or N-) and the time from surgery to randomisation (< or = 21 days or > 22 days). The surgical procedures for sub-total or total gastrectomy with D2 dissection were standardised among the participating centres. RESULTS Between December 1992 and December 1997, 274 patients were enrolled: 137 in the treatment arm and 137 in the control arm. The majority of the patients (90%) were N+. After a median follow up of 66 months (range 2-83), the 5-year overall survival (OS) was 52% in the treatment arm and 48% in the control arm [hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.65-1.34]; the 5-year disease-free survival (DFS) was 49% and 44%, respectively (HR: 0.83; 95% CI 0.59-1.17). Among the patients with N-/N+ (1-6), the 5-year OS was 61% in the treatment group and 60% in the control group; in those with N+ (1-6), it was 42% and 22%. The treatment was completed by 87% of patients. Drug-related grade 3/4 WHO toxicities included leukopenia (21%), nausea and vomiting (14%), mucositis (9%), neutropenia (3%) and thrombocytopenia (2%). There were two deaths due to sepsis. CONCLUSIONS Although our results are not statistically significant, there was a limited relative risk reduction in the patients receiving adjuvant therapy (17% in DFS and 7% in OS). The data suggest that D2 surgery may have a favourable impact on OS.
Collapse
Affiliation(s)
- E Bajetta
- Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milano, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Franciosi V, Barbieri R, Vasini G, Aitini E, Cacciani C, Capra R, Greco F, Bozzetti C, Cascinu S. The combination of gemcitabine and oxaliplatin (GEM-OXAL) is feasible in patients with poor prognosis advanced non-small cell lung cancer (NSCLC). Results of a phase II study. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80692-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Favaretto A, Ardizzoni A, Tixi L, Antilli A, Boni L, Aitini E, Barbera S, Raimondi M, Ziade A, Porcile G, Cacciani G, Spatafora M, Donghi M, Rosso R, Paccagnella A, Salvati F. Full dose (FD) chemotherapy (CT) plus lenograstim and low dose (LD) CT in elderly SCLC patients. A phase II randomized fonicap-GSTPV study. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80023-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Zinzani PL, Magagnoli M, Moretti L, Battista R, Ronconi F, De Renzo A, Zaccaria A, Gentilini P, Guardigni L, Gherlinzoni F, Cellini C, Fattori PP, Bendandi M, Bocchia M, Aitini E, Tura S. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica 1999; 84:1002-6. [PMID: 10553160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
BACKGROUND AND OBJECTIVE A prospective study to evaluate the role of fludarabine alone or in combination with idarubicin in untreated patients with mantle cell lymphoma (MCL). DESIGN AND METHODS Twenty-nine untreated patients with mantle cell lymphoma were stochastically treated with intravenous fludarabine at a dose of 25 mg/m(2)/day for 5 days (11 patients) or with a combination of fludarabine and idarubicin (FLU-ID) (fludarabine 25 mg/m(2) i.v. on days 1 to 3 and idarubicin 12 mg/m(2) i.v. on day 1 (18 patients). For both regimens, cycles were given at three-week intervals for a total of six courses. According to the International Prognostic Index, the most part of high-intermediate and high risk factor patients were in the FLU-ID subset: 7 (39%) patients vs. 2 (18%) in the fludarabine alone subset. RESULTS Of the 29 patients, 8 (28%) obtained a complete response and 10 (35%) a partial response, with an overall response rate of 63%. The remaining 11 (37%) patients did not respond to the therapy. The overall response rates were 64% (7 patients) in the fludarabine group and 61% (11 patients) in the FLU-ID group. The complete response rate was 27% (3 patients) for fludarabine and 28% (5 patients) for FLU-ID. The toxicity was mild in terms of neutropenia and infections, and no fatalities occurred due to drug-induced side effects. INTERPRETATION AND CONCLUSIONS These results suggest the efficacy of fludarabine alone or in combination with idarubicin in MCL patients. It will be important to increase this experience and to assess other fludarabine-containing regimens, in particular with cyclophosphamide plus idarubicin and with mitoxantrone and or cyclophosphamide, to test the true role of this approach in MCL.
Collapse
Affiliation(s)
- P L Zinzani
- Istituto di Ematologia e Oncologia Medica "Seràgnoli", Policlinico S.Orsola, via Massarenti 9, 40138 Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33-8. [PMID: 10381495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
Age is a risk factor and a prognostic parameter in elderly aggressive-histology non-Hodgkin's lymphoma (NHL) patients. Several adapted chemotherapeutic regimens have recently been designed and tested on elderly patients. Several of these trials have shown that older aggressive-histology NHL patients can benefit from specific and adequate treatment capable of curing a percentage of these patients. Between January 1992 and September 1997, 350 previously untreated aggressive-histology NHL patients greater than 60 years of age were treated with a combination therapy including cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (VNCOP-B). Complete remission (CR) was achieved by 202 (58%) patients and partial remission (PR) by 87 (25%), whereas the remaining 61 (17%) patients were nonresponders. The overall response rate (CR + PR) was 83%. Clinical and hematologic toxicities were modest, because 71% of the patients received granulocyte colony-stimulating factor (G-CSF). The CR rates for the three age groups (60 to 69, 70 to 79, and >/=80 years) were similar: 61%, 59%, and 56%, respectively. At 5 years, the relapse-free survival rate was 65%, the overall survival rate was 49%, and the failure-free survival rate was 33%. In the multivariate analysis, prognostic factors associated with longer survival or longer relapse-free survival turned out to be localized disease stage (P =.001) and good performance status (P =.0002). Application of the International Prognostic Factor Index was significantly associated with outcome (P =.001). These data confirm on a large cohort of patients that the VNCOP-B regimen is effective in inducing good CR and relapse-free survival rates with only moderate toxic effects in elderly aggressive-histology NHL.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Pari F, Zamagni MD, Carnevali C, Pagani M, Rabbi C, Cantore M, Cavazzini G, Aitini E, Smerieri F. [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches]. Recenti Prog Med 1999; 90:169-72. [PMID: 10228358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Mastocytosis is a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells in skin, bone marrow, bone, gastrointestinal tract, liver, spleen and lymph nodes. Today, regarding its biological features, mastocytosis (with or without myeloid accompanying disorders) is considered to be a hematologic disease. The classification proposed by Metcalfe in 1991 is the most useful in caring for patients with mastocytosis. In this classification 4 groups are described: 1) indolent mastocytosis with or without extracutaneous involvement; 2) systemic mastocytosis with an associated hematologic disorder; 3) aggressive mastocytosis; 4) mast-cell leukemia. Cutaneous mastocytosis typically presents as urticaria pigmentosa or diffuse cutaneous mastocytosis and these patients usually have a benign course. On the contrary, systemic mastocytosis is a disease with an increased risk to develop an aggressive hematologic disorder. In these patients a second hematologic process, such as myeloproliferative or myelodysplastic syndrome or acute leukemia, may occur. These patients often present without skin involvement and they have a very poor prognosis. Mast cell is a medium-sized granulated cell releasing chemical mediators (histamine, heparin, protease and cytokines). Mast cells originate from pluripotent hemopoietic progenitor cells that express the CD34 antigen. Mast cells are present in the bone marrow and are distributed throughout the connective tissues. Recently a mast-cell growth factor (MGF) has been identified. Clinical symptoms occur from the release of chemical mediators and the pathologic infiltration of cells. Although no effective therapy for patients with Mastocytosis is known, some patients may benefit from corticosteroid and interferon alpha treatment. The present article gives an overview of current knowledge about the biology, heterogeneity and treatment of human mastocytosis.
Collapse
Affiliation(s)
- F Pari
- Divisione di Oncologia ed Ematologia, Ospedale Carlo Poma, Mantova
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Mambrini A, Cavazzini G, Pari F, Rabbi C, Cantore M, Zamagni MD, Amadori M, Riitano G, Schiavini A, Bosi A, Aitini E, Smerieri F. [Pulmonary metastasis from an eccrine carcinoma: thoracic perfusion with the aorto-caval stop-flow technique. Description of a clinical case]. MINERVA CHIR 1998; 53:441-5. [PMID: 9780638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
A case of a 64-year-old man with eccrine carcinoma arising from hand skin is reported. At the time of diagnosis he showed bilateral pneumonic metastases. Although the patient underwent two systemic chemotherapy lines, he showed further progressive disease of the lung. For this reason a third chemotherapy line was started through thoracic stop-flow infusion. In this way, a five month stable disease had been achieved. The patient died 7 months later for progressive disease. The rarity of this disease, the uncertain treatment, the feasibility and efficacy of thoracic stop-flow infusion are underlined and further studies are suggested.
Collapse
Affiliation(s)
- A Mambrini
- Divisione di Oncologia Medica, Azienda Ospedaliera C. Poma, Mantova
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|